ATI RN
ATI Pharmacology Proctored Exam
1. A healthcare provider is preparing to administer Belimumab to a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare provider plan to take?
- A. Warm the medication to room temperature before administering.
- B. Administer the medication by IV bolus over 5 minutes.
- C. Dilute the medication in a 5% dextrose and water solution.
- D. Monitor the client for hypersensitivity reactions.
Correct answer: D
Rationale: Correct Answer: Monitoring the client for hypersensitivity reactions is crucial when administering Belimumab due to its known potential for severe infusion reactions and anaphylaxis. The healthcare provider should closely observe the client during the administration to promptly identify and manage any hypersensitivity reactions that may occur. Choice A is incorrect because warming Belimumab is not necessary before administration. Choice B is incorrect as Belimumab should not be administered as an IV bolus over 5 minutes; it should be given as an IV infusion over a longer duration. Choice C is incorrect as Belimumab should not be diluted in a 5% dextrose and water solution.
2. What is pharmacodynamics?
- A. The medical reference summarizing standards of drug purity, strength, and directions for synthesis
- B. The drug's actions at receptor sites and the physiological, chemical, and behavioral effects produced by these actions
- C. The maximum response that a drug can produce
- D. Movements of the drugs throughout the body
Correct answer: B
Rationale: Pharmacodynamics refers to the drug's actions at receptor sites and the physiological, chemical, and behavioral effects produced by these actions. It involves understanding how drugs interact with the body at the molecular level to produce their effects, including mechanisms of action, receptor binding, and downstream physiological responses. Choice A is incorrect because it describes pharmacopeia, which is a reference book containing standards for drugs. Choice C refers to efficacy, which is the maximum effect a drug can produce. Choice D describes pharmacokinetics, which focuses on the movement of drugs within the body.
3. A client is starting therapy with doxorubicin. Which of the following findings should the nurse instruct the client to report?
- A. Hair loss
- B. Fatigue
- C. Sore throat
- D. Red urine
Correct answer: C
Rationale: The correct answer is 'C: Sore throat.' Doxorubicin is known to have immunosuppressive effects, which can predispose the client to infections. A sore throat can be an early sign of infection, and prompt reporting to the healthcare provider is crucial to initiate appropriate interventions and prevent complications. Choices A, B, and D are incorrect because hair loss, fatigue, and red urine are common side effects of doxorubicin and are typically expected during therapy. While these side effects should be monitored, they do not require immediate reporting unless they become severe or concerning.
4. A client is receiving treatment with bevacizumab. Which of the following findings should the nurse monitor?
- A. Hypertension
- B. Hypokalemia
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Correct Answer: A. Bevacizumab is known to cause hypertension as a common adverse effect. The nurse should closely monitor the client's blood pressure to detect and manage this potential side effect promptly. Choice B, hypokalemia, is not typically associated with bevacizumab treatment. Choice C, hyperglycemia, is not a common adverse effect of bevacizumab. Choice D, hypocalcemia, is not a recognized side effect of bevacizumab.
5. A school-age child has a new prescription for Atomoxetine. The nurse should monitor the client for which of the following adverse effects of this medication?
- A. Kidney toxicity
- B. Liver damage
- C. Seizure activity
- D. Adrenal insufficiency
Correct answer: B
Rationale: Liver damage is an adverse effect of Atomoxetine. The nurse should monitor for manifestations such as jaundice, upper abdominal tenderness, darkening of urine, and elevated liver enzymes. It is crucial to be vigilant for signs of liver damage to ensure early detection and intervention to prevent further complications. Kidney toxicity is not a common adverse effect of Atomoxetine. Seizure activity and adrenal insufficiency are also not typically associated with this medication.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access